uric acid has been researched along with Synovitis in 77 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Synovitis: Inflammation of the SYNOVIAL MEMBRANE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the ability of a proprietary antagonist of E-type prostanoid receptor (EP) 4, grapiprant, and carprofen to attenuate lameness attributable to urate-induced synovitis in dogs." | 9.30 | Comparison of two inhibitors of E-type prostanoid receptor four and carprofen in dogs with experimentally induced acute synovitis. ( Budsberg, SC; Kleine, SA; Norton, MM; Sandberg, GS, 2019) |
| "In this double-blind, placebo-controlled study, 314 subjects with hyperuricemia (serum uric acid [UA] level of ≥7." | 9.24 | Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. ( Choi, HK; Dalbeth, N; Gunawardhana, L; Hunt, B; MacDonald, PA; Palmer, WE; Saag, KG; Thienel, U, 2017) |
| "A randomized, placebo-controlled, four-period cross-over laboratory study involving eight dogs was conducted to confirm the effective analgesic dose of firocoxib, a selective COX-2 inhibitor, in a synovitis model of arthritis." | 9.13 | Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs. ( Hanson, PD; Hazewinkel, HA; Pollmeier, M; Theyse, LF; van den Brom, WE, 2008) |
| "This positive-control study evaluated the efficacy of firocoxib versus carprofen, deracoxib, and meloxicam for the prevention of pain and inflammation in a urate crystal synovitis model of lameness." | 9.12 | Firocoxib efficacy preventing urate-induced synovitis, pain, and inflammation in dogs. ( Drag, M; Hanson, PD; Kunkle, BN; Romano, D, 2007) |
| " These physiological characteristics have promoted the study of poly-gallic acid (PGAL), a poly-oxidized form of gallic acid reported to be effective in in vitro models of inflammation." | 8.12 | Anti-inflammatory and Antioxidant Effect of Poly-gallic Acid (PGAL) in an In Vitro Model of Synovitis Induced by Monosodium Urate Crystals. ( Fernández-Torres, J; Gimeno, M; Luján-Juárez, IA; Martínez-Flores, K; Martínez-López, V; Montaño-Armendariz, N; Sánchez-Sánchez, R; Zamudio-Cuevas, Y, 2022) |
| " We reasoned that AKI resulted from hyperuricemia during MZ administration because serum concentrations of uric acid (31." | 7.78 | A case of acute kidney injury with marked hyperuricemia during mizoribine administration. ( Kohno, S; Nishino, T; Obata, Y; Ohta, Y; Shinzato, K; Shinzato, T; Yamashita, H, 2012) |
| "To evaluate the efficacy of epidurally administered deracoxib to mediate the signs of a sodium urate crystal-induced stifle synovitis in dogs, and to compare the efficacy of epidural versus subcutaneously administered deracoxib." | 7.73 | The effects of epidural deracoxib on the ground reaction forces in an acute stifle synovitis model. ( Broadstone, R; Inzana, K; Johnston, S; Karnik, PS; Ward, D, 2006) |
| "Carprofen was also somewhat effective in attenuating the severity of urate-induced synovitis but to a lesser degree than the medium dose of deracoxib." | 6.70 | Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. ( Buonomo, FC; Millis, DL; Moyers, T; Weigel, JP, 2002) |
| "To investigate the ability of a proprietary antagonist of E-type prostanoid receptor (EP) 4, grapiprant, and carprofen to attenuate lameness attributable to urate-induced synovitis in dogs." | 5.30 | Comparison of two inhibitors of E-type prostanoid receptor four and carprofen in dogs with experimentally induced acute synovitis. ( Budsberg, SC; Kleine, SA; Norton, MM; Sandberg, GS, 2019) |
| "Lidocaine was used in high doses or lower doses comparable to those used clinically for cardiac arrhythmias." | 5.27 | Lidocaine inhibits leukocyte migration and phagocytosis in monosodium urate crystal-induced synovitis in dogs. ( Clayburne, G; Paul, H; Schumacher, HR, 1983) |
| "In this double-blind, placebo-controlled study, 314 subjects with hyperuricemia (serum uric acid [UA] level of ≥7." | 5.24 | Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. ( Choi, HK; Dalbeth, N; Gunawardhana, L; Hunt, B; MacDonald, PA; Palmer, WE; Saag, KG; Thienel, U, 2017) |
| "The objectives of this study were to establish dose-response and blood concentration-response relationships for robenacoxib, a novel nonsteroidal anti-inflammatory drug with selectivity for inhibition of the cyclooxygenase (COX)-2 isoenzyme, in a canine model of synovitis." | 5.14 | Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog. ( Jung, M; King, JN; Lees, P; Schmid, VB; Seewald, W; Spreng, DE, 2010) |
| "A randomized, placebo-controlled, four-period cross-over laboratory study involving eight dogs was conducted to confirm the effective analgesic dose of firocoxib, a selective COX-2 inhibitor, in a synovitis model of arthritis." | 5.13 | Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs. ( Hanson, PD; Hazewinkel, HA; Pollmeier, M; Theyse, LF; van den Brom, WE, 2008) |
| "This positive-control study evaluated the efficacy of firocoxib versus carprofen, deracoxib, and meloxicam for the prevention of pain and inflammation in a urate crystal synovitis model of lameness." | 5.12 | Firocoxib efficacy preventing urate-induced synovitis, pain, and inflammation in dogs. ( Drag, M; Hanson, PD; Kunkle, BN; Romano, D, 2007) |
| " These physiological characteristics have promoted the study of poly-gallic acid (PGAL), a poly-oxidized form of gallic acid reported to be effective in in vitro models of inflammation." | 4.12 | Anti-inflammatory and Antioxidant Effect of Poly-gallic Acid (PGAL) in an In Vitro Model of Synovitis Induced by Monosodium Urate Crystals. ( Fernández-Torres, J; Gimeno, M; Luján-Juárez, IA; Martínez-Flores, K; Martínez-López, V; Montaño-Armendariz, N; Sánchez-Sánchez, R; Zamudio-Cuevas, Y, 2022) |
| " We reasoned that AKI resulted from hyperuricemia during MZ administration because serum concentrations of uric acid (31." | 3.78 | A case of acute kidney injury with marked hyperuricemia during mizoribine administration. ( Kohno, S; Nishino, T; Obata, Y; Ohta, Y; Shinzato, K; Shinzato, T; Yamashita, H, 2012) |
| "To evaluate the efficacy of epidurally administered deracoxib to mediate the signs of a sodium urate crystal-induced stifle synovitis in dogs, and to compare the efficacy of epidural versus subcutaneously administered deracoxib." | 3.73 | The effects of epidural deracoxib on the ground reaction forces in an acute stifle synovitis model. ( Broadstone, R; Inzana, K; Johnston, S; Karnik, PS; Ward, D, 2006) |
| " Progression of the chronic synovitis in zymosan-induced arthritis (ZYA) was associated with increased nitrite and nitrotyrosine (3-NT) levels in the joint exudates that paralleled a progressive loss of the GAG content." | 3.72 | Reactive nitrogen species scavenging, rather than nitric oxide inhibition, protects from articular cartilage damage in rat zymosan-induced arthritis. ( Bezerra, MM; Brain, SD; da Rocha, FA; de Melo, LB; Greenacre, S; Jerônimo, SM; Keeble, J, 2004) |
| " In this study, we show that the inflammatory microcrystals monosodium urate monohydrate (MSU) and calcium pyrophosphate dihydrate (CPPD), the major mediators of gout and pseudogout, differentially regulate the production of these two chemokines by human neutrophils." | 3.69 | Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. ( Hachicha, M; McColl, SR; Naccache, PH, 1995) |
| " Synovial fluid and plasma gentamicin concentrations were measured for 14 days after implantation, and pharmacokinetic parameters modeled using statistical moment analyses." | 2.79 | Intra-articular pharmacokinetics of a gentamicin impregnated collagen sponge in the canine stifle: an experimental study. ( Gibson, TW; Hayes, GM; Johnson, RJ; Moens, NM; Monteiro, B, 2014) |
| "For firocoxib, there was no difference from baseline scores in lameness scores at any point." | 2.77 | Efficacy of ABT-116, an antagonist of transient receptor potential vanilloid type 1, in providing analgesia for dogs with chemically induced synovitis. ( Al-Nadaf, S; Budsberg, SC; Cathcart, CJ; Johnston, SA; Reynolds, LR, 2012) |
| "On the fourth day after initiation of treatment, synovitis was induced via intra-articular injection of SU 1 hour before administration of the last treatment dose." | 2.76 | Effect of perzinfotel and a proprietary phospholipase A(2) inhibitor on kinetic gait and subjective lameness scores in dogs with sodium urate-induced synovitis. ( Al-Nadaf, S; Budsberg, SC; Cathcart, CJ; Clark, JD; Eppler, CM; Reynolds, LR; Torres, BT; Zwijnenberg, RJ, 2011) |
| "Carprofen was also somewhat effective in attenuating the severity of urate-induced synovitis but to a lesser degree than the medium dose of deracoxib." | 2.70 | Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. ( Buonomo, FC; Millis, DL; Moyers, T; Weigel, JP, 2002) |
| "A blinded, randomized, controlled single crossover design study was performed to determine the efficacy of meloxicam, using 2 dosage groups." | 2.68 | Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs. ( Budsberg, SC; Cross, AR; Keefe, TJ, 1997) |
| "Carpal tunnel syndrome is well known in gout (28 reported cases), and is secondary to gouty tenosynovitis." | 2.39 | [Double tunnel syndrome of the upper limb in tophaceous gout. Apropos of a case]. ( Jacoulet, P, 1994) |
| "Gouty arthritis is the one of the most painful arthritis and is caused by an inflammatory reaction." | 1.56 | Astaxanthin attenuates joint inflammation induced by monosodium urate crystals. ( Ho, YJ; Hsieh, TH; Lee, CH; Lee, HS; Liu, FC; Lu, JW; Peng, YJ; Wang, CC; Wu, CC, 2020) |
| "Synovitis was then induced in the left stifle joint by intra-articular injection of monosodium urate." | 1.34 | Kinetic gait and subjective analysis of the effects of a tachykinin receptor antagonist in dogs with sodium urate-induced synovitis. ( Budsberg, SC; Claxton, RF; Punke, JP; Reynolds, LR; Speas, AL, 2007) |
| "Lidocaine was used in high doses or lower doses comparable to those used clinically for cardiac arrhythmias." | 1.27 | Lidocaine inhibits leukocyte migration and phagocytosis in monosodium urate crystal-induced synovitis in dogs. ( Clayburne, G; Paul, H; Schumacher, HR, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (49.35) | 18.7374 |
| 1990's | 7 (9.09) | 18.2507 |
| 2000's | 12 (15.58) | 29.6817 |
| 2010's | 17 (22.08) | 24.3611 |
| 2020's | 3 (3.90) | 2.80 |
| Authors | Studies |
|---|---|
| Zamudio-Cuevas, Y | 1 |
| Martínez-López, V | 1 |
| Luján-Juárez, IA | 1 |
| Montaño-Armendariz, N | 1 |
| Martínez-Flores, K | 1 |
| Fernández-Torres, J | 1 |
| Gimeno, M | 1 |
| Sánchez-Sánchez, R | 1 |
| Budsberg, SC | 6 |
| Kleine, SA | 1 |
| Norton, MM | 1 |
| Sandberg, GS | 1 |
| Peng, YJ | 1 |
| Lu, JW | 1 |
| Liu, FC | 1 |
| Lee, CH | 2 |
| Lee, HS | 2 |
| Ho, YJ | 1 |
| Hsieh, TH | 1 |
| Wu, CC | 1 |
| Wang, CC | 1 |
| Zhang, W | 1 |
| Zhao, D | 1 |
| Wu, M | 1 |
| Chen, W | 1 |
| Jin, Z | 1 |
| Zhang, H | 1 |
| Dalbeth, N | 1 |
| Saag, KG | 1 |
| Palmer, WE | 1 |
| Choi, HK | 1 |
| Hunt, B | 1 |
| MacDonald, PA | 1 |
| Thienel, U | 1 |
| Gunawardhana, L | 1 |
| Estevez-Garcia, IO | 1 |
| Gallegos-Nava, S | 1 |
| Vera-Pérez, E | 1 |
| Silveira, LH | 1 |
| Ventura-Ríos, L | 1 |
| Vancini, G | 1 |
| Hernández-Díaz, C | 1 |
| Sánchez-Muñoz, F | 1 |
| Ballinas-Verdugo, MA | 1 |
| Gutierrez, M | 1 |
| Pineda, C | 1 |
| Rodriguez-Henriquez, P | 1 |
| Castillo-Martínez, D | 1 |
| Amezcua-Guerra, LM | 1 |
| Xiao, L | 1 |
| Lin, S | 1 |
| Zhan, F | 1 |
| Courtney, P | 1 |
| Doherty, M | 1 |
| Hayes, GM | 1 |
| Gibson, TW | 1 |
| Moens, NM | 1 |
| Monteiro, B | 1 |
| Johnson, RJ | 1 |
| Hassan, EA | 2 |
| Lambrechts, NE | 2 |
| Moore, GE | 1 |
| Weng, HY | 2 |
| Heng, HG | 1 |
| Breur, GJ | 2 |
| Torres, BT | 2 |
| Jimenez, DA | 1 |
| Borer, LR | 1 |
| Seewald, W | 2 |
| Peel, JE | 1 |
| King, JN | 2 |
| Snyder, PW | 1 |
| Tsai, HC | 1 |
| Salter, DM | 1 |
| Carroll, GL | 2 |
| Narbe, R | 2 |
| Peterson, K | 2 |
| Kerwin, SC | 2 |
| Taylor, L | 2 |
| DeBoer, M | 1 |
| Torres, R | 1 |
| Macdonald, L | 1 |
| Croll, SD | 1 |
| Reinhardt, J | 1 |
| Dore, A | 1 |
| Stevens, S | 1 |
| Hylton, DM | 1 |
| Rudge, JS | 1 |
| Liu-Bryan, R | 2 |
| Terkeltaub, RA | 3 |
| Yancopoulos, GD | 1 |
| Murphy, AJ | 1 |
| Schmid, VB | 1 |
| Spreng, DE | 1 |
| Jung, M | 1 |
| Lees, P | 1 |
| Regule, D | 1 |
| Feldsein, JD | 1 |
| Wilke, VL | 1 |
| Evans, RB | 1 |
| Conzemius, MG | 1 |
| Zwijnenberg, RJ | 1 |
| Eppler, CM | 1 |
| Clark, JD | 1 |
| Cathcart, CJ | 2 |
| Reynolds, LR | 3 |
| Al-Nadaf, S | 2 |
| Hartsfield, SM | 1 |
| Johnston, SA | 1 |
| Nishino, T | 1 |
| Shinzato, T | 1 |
| Ohta, Y | 1 |
| Yamashita, H | 1 |
| Obata, Y | 1 |
| Shinzato, K | 1 |
| Kohno, S | 1 |
| Millis, DL | 1 |
| Weigel, JP | 1 |
| Moyers, T | 1 |
| Buonomo, FC | 1 |
| MCCARTY, DJ | 4 |
| Bezerra, MM | 1 |
| Brain, SD | 1 |
| Greenacre, S | 1 |
| Jerônimo, SM | 1 |
| de Melo, LB | 1 |
| Keeble, J | 1 |
| da Rocha, FA | 1 |
| Tramontini, N | 1 |
| Huber, C | 1 |
| Kilgore, KS | 1 |
| Karnik, PS | 1 |
| Johnston, S | 1 |
| Ward, D | 1 |
| Broadstone, R | 1 |
| Inzana, K | 1 |
| Hazewinkel, HA | 1 |
| van den Brom, WE | 1 |
| Theyse, LF | 1 |
| Pollmeier, M | 1 |
| Hanson, PD | 2 |
| Drag, M | 1 |
| Kunkle, BN | 1 |
| Romano, D | 1 |
| Punke, JP | 1 |
| Speas, AL | 1 |
| Claxton, RF | 1 |
| Moskowitz, RW | 1 |
| Katz, D | 1 |
| Dieppe, PA | 1 |
| Wigley, FM | 1 |
| Fine, IT | 1 |
| Newcombe, DS | 1 |
| Sedgwick, AD | 1 |
| Sin, YM | 1 |
| Edwards, JC | 1 |
| Willoughby, DA | 1 |
| Merritt, JL | 1 |
| Hunder, GG | 1 |
| Paul, H | 1 |
| Clayburne, G | 1 |
| Schumacher, HR | 4 |
| Luchikhina, LV | 1 |
| Matzkies, F | 1 |
| Hachicha, M | 1 |
| Naccache, PH | 1 |
| McColl, SR | 1 |
| Jacoulet, P | 1 |
| Blair, JM | 1 |
| Sorensen, LB | 1 |
| Arnsdorf, MF | 1 |
| Lal, R | 1 |
| Ortiz-Bravo, E | 1 |
| Cross, AR | 1 |
| Keefe, TJ | 1 |
| Fam, AG | 1 |
| Reis, MD | 1 |
| Szalai, JP | 1 |
| Pascual, E | 1 |
| Nuño Mateo, FJ | 1 |
| Noval Menéndez, J | 1 |
| Mazorra Iraculis, M | 1 |
| Campoamor Serrano, M | 1 |
| Müller, W | 1 |
| Guard, CL | 1 |
| Byman, KW | 1 |
| Schwark, WS | 1 |
| Carlson, RP | 1 |
| Chang, J | 1 |
| Datko, LJ | 1 |
| Lewis, AJ | 1 |
| Dubinsky, B | 1 |
| Gebre-Mariam, S | 1 |
| Capetola, RJ | 1 |
| Rosenthale, ME | 3 |
| Jeremy, R | 1 |
| Rhodes, FA | 1 |
| Sharp, JT | 1 |
| Rawls, WE | 1 |
| Mason, M | 1 |
| Phelps, P | 3 |
| Pyenson, J | 1 |
| Schilling, F | 1 |
| Agudelo, CA | 2 |
| MacCarty, DJ | 1 |
| Silcox, DC | 1 |
| Begany, AJ | 1 |
| Dervinis, A | 1 |
| Malis, JL | 1 |
| Shriver, DA | 1 |
| Datko, SL | 1 |
| Gluckman, MI | 1 |
| Scott, JT | 1 |
| Glynn, LE | 1 |
| Lumachi, B | 1 |
| Grahame, R | 1 |
| Sutor, DJ | 1 |
| Mitchener, MB | 1 |
| Klein, G | 1 |
| Spilberg, I | 1 |
| Osterland, CK | 1 |
| Steele, AD | 1 |
| Ripault, J | 1 |
| Benoist, M | 1 |
| Nguyen-Huy, D | 1 |
| Bloch-Michel, H | 1 |
| McCollum, DE | 1 |
| Mathews, RS | 1 |
| O'NEIL, MT | 1 |
| Hüttl, S | 1 |
| Hüttlová, O | 1 |
| Munthe, E | 1 |
| Quagliata, F | 1 |
| Sanders, PM | 1 |
| Gardner, DL | 1 |
| Solnica, F | 1 |
| Kassarich, J | 1 |
| Schneider, F | 1 |
| Campanacci, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects With Early Gout[NCT01078389] | Phase 2 | 314 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept[NCT04012294] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-08-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of this single joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst). Individual erosion scores were summed to a maximum erosion score of 5 for joints in the hands and 10 for joints in the feet. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 24 | |
| Febuxostat 40 mg or 80 mg | 0.16 | 0.01 |
| Placebo | 0.11 | 0.01 |
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 24 (n=78,74) | |
| Febuxostat 40 mg or 80 mg | 0.36 | 0.17 |
| Placebo | 0.17 | 0.11 |
The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of the single affected joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) and Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst). The Erosion Score and the JSN Score were summed for the Total Score. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 24(n=81,76) | |
| Febuxostat 40 mg or 80 mg | 0.85 | 0.00 |
| Placebo | 0.77 | 0.05 |
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst) for a total JSN score range of 0 to 208. The Erosion Score and the JSN Score were combined for a total possible score of 0 to 528. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 24 (n=78,74) | |
| Febuxostat 40 mg or 80 mg | 4.98 | 0.31 |
| Placebo | 4.56 | 0.29 |
The single affected joint was defined as the joint with the history of the first acute gout flare. Magnetic Resonance Imaging (MRI) was evaluated using the Rheumatoid Arthritis MRI Score (RAMRIS). Bone erosion in the proximal and distal location were each assessed in the affected joint using an 11-point scale where 0=no erosion (best) to 10=91-100% bone eroded (worst) for a bone erosion score range of 0 to 20. Bone marrow edema in the proximal and distal location were each assessed using a 4-point scale where 0=no edema (best) to 3=67-100% edema (worst) for a bone marrow edema (BME) score range of 0 to 6. Synovitis was assessed in the affected joint using a 4-point scale where 0=normal (best) to 3=severe (worst). Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Synovitis:Baseline (BL)(n=82,76) | Synovitis:Change from Baseline (n=75,67) | Erosion (Distal+Proximal):Baseline (n=84,77) | Erosion (Distal+Proximal):Change from BL(n=79,69) | Edema (Distal+Proximal):Baseline (BL) (n=81,75) | Edema (Distal+Proximal):Change from BL(n=77,66) | |
| Febuxostat 40 mg or 80 mg | 1.29 | -0.43 | 1.63 | -0.01 | 0.73 | -0.36 |
| Placebo | 1.09 | -0.07 | 1.48 | 0.04 | 0.51 | -0.10 |
8 reviews available for uric acid and Synovitis
| Article | Year |
|---|---|
Joint aspiration and injection and synovial fluid analysis.
Topics: Arthritis, Gouty; Calcium Pyrophosphate; Glucocorticoids; Humans; Injections, Intra-Articular; Knee | 2013 |
An update on inflammatory arthropathies including pharmacologic management and preoperative considerations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Diagnosis, Differential; Foot Diseases; Foot Joi | 2010 |
Crystal deposition and inflammation.
Topics: Arthritis; Calcium Oxalate; Calcium Pyrophosphate; Cholesterol; Crystallization; Gout; Humans; Hydro | 1984 |
[Double tunnel syndrome of the upper limb in tophaceous gout. Apropos of a case].
Topics: Aged; Carpal Tunnel Syndrome; Fingers; Gout; Hand; Humans; Male; Median Nerve; Nerve Compression Syn | 1994 |
Gout update: from lab to the clinic and back.
Topics: Crystallization; Gout; Gout Suppressants; Humans; Organ Transplantation; Synovitis; Uric Acid | 2000 |
[Inflammatory joint effusion. A diagnositic and therapeutic problem].
Topics: Adrenal Cortex Hormones; Chronic Disease; Diagnosis, Differential; Erbium; Exudates and Transudates; | 1979 |
The antialgesic drugs: human therapeutic correlates of their potency in laboratory animal models of hyperalgesia.
Topics: Acetylcholine; Administration, Oral; Analgesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ar | 1987 |
On the crystal deposition diseases.
Topics: Adult; Aged; Arthritis; Calcinosis; Diphosphates; Female; Gout; Humans; Joint Diseases; Male; Middle | 1970 |
13 trials available for uric acid and Synovitis
| Article | Year |
|---|---|
Comparison of two inhibitors of E-type prostanoid receptor four and carprofen in dogs with experimentally induced acute synovitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cross-Over Studies; Dog Diseases; Dogs | 2019 |
Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Join | 2017 |
Intra-articular pharmacokinetics of a gentamicin impregnated collagen sponge in the canine stifle: an experimental study.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Collagen; Dogs; Drug Implants; Female; Gentamicins | 2014 |
Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxyge | 2017 |
Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Diphenylamine; Dog Diseases; Dog | 2010 |
Effect of perzinfotel and a proprietary phospholipase A(2) inhibitor on kinetic gait and subjective lameness scores in dogs with sodium urate-induced synovitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Azabicyclo Compounds; Blood Proteins; Carbazoles; | 2011 |
Dose range finding study for the efficacy of meloxicam administered prior to sodium urate-induced synovitis in cats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cats; Cross-Over Studies; Dose-Response Relationsh | 2011 |
Efficacy of ABT-116, an antagonist of transient receptor potential vanilloid type 1, in providing analgesia for dogs with chemically induced synovitis.
Topics: 4-Butyrolactone; Analgesia; Animals; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Dog Diseases; | 2012 |
Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cyclooxygenase I | 2002 |
Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Carbazoles; Cross-Over | 2008 |
Firocoxib efficacy preventing urate-induced synovitis, pain, and inflammation in dogs.
Topics: 4-Butyrolactone; Animals; Carbazoles; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Female; Lamen | 2007 |
Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Cyclooxygenase Inhibitors; Dog | 1997 |
Suppressive effects of indoxole in crystal-induced synovitis in man.
Topics: Adult; Analgesics; Anti-Inflammatory Agents; Body Temperature; Clinical Trials as Topic; Humans; Ind | 1967 |
56 other studies available for uric acid and Synovitis
| Article | Year |
|---|---|
Anti-inflammatory and Antioxidant Effect of Poly-gallic Acid (PGAL) in an In Vitro Model of Synovitis Induced by Monosodium Urate Crystals.
Topics: Anti-Inflammatory Agents; Antioxidants; Gallic Acid; Gout; Humans; Inflammation; Polyglutamic Acid; | 2022 |
Astaxanthin attenuates joint inflammation induced by monosodium urate crystals.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Cells, Cultured; Chondrocytes; Cyclooxygenase 2 | 2020 |
Ultrasound Evaluation of Three Outcome Domains in the Follow-up of Urate-Lowering Therapy in Gout: An Observational Study.
Topics: Adult; Arthritis; Bone Diseases; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Hum | 2021 |
Levels of Cytokines and MicroRNAs in Individuals With Asymptomatic Hyperuricemia and Ultrasonographic Findings of Gout: A Bench-to-Bedside Approach.
Topics: Adult; Aged; Asymptomatic Diseases; Biomarkers; Case-Control Studies; Chronic Disease; Circulating M | 2018 |
The association between serum uric acid level and changes of MRI findings in knee osteoarthritis: A retrospective study (A STROBE-compliant article).
Topics: Aged; Biomarkers; Body Mass Index; Creatinine; Disease Progression; Female; Humans; Logistic Models; | 2019 |
Development of a model to induce transient synovitis and lameness in the hip joint of dogs.
Topics: Animals; Biomechanical Phenomena; Disease Models, Animal; Dog Diseases; Dogs; Female; Gait; Injectio | 2015 |
Elevated synovial fluid concentration of adenosine triphosphate in dogs with osteoarthritis or sodium urate-induced synovitis of the stifle.
Topics: Adenosine Triphosphate; Animals; Dog Diseases; Dogs; Female; Male; Osteoarthritis; Stifle; Synovial | 2016 |
Effects of denervation of the hip joint on results of clinical observations and instrumented gait analysis in dogs with sodium urate crystal-induced synovitis.
Topics: Animals; Biomechanical Phenomena; Denervation; Dog Diseases; Dogs; Female; Gait; Hip Joint; Kinetics | 2016 |
Inhibition of cyclooxygenase 2 expression by diallyl sulfide on joint inflammation induced by urate crystal and IL-1beta.
Topics: Allyl Compounds; Animals; Arthritis, Experimental; Cartilage, Articular; Cell Line; Cells, Cultured; | 2009 |
A pilot study: sodium urate synovitis as an acute model of inflammatory response using objective and subjective criteria to evaluate arthritic pain in cats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Area Under Curve; Cats; Female; Infl | 2008 |
Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Gouty; Biomarkers; Colchicine; Cytokines; Disease Model | 2009 |
Serum cortisol concentration and force plate analysis in the assessment of pain associated with sodium urate-induced acute synovitis in dogs.
Topics: Animals; Biomarkers; Dog Diseases; Dogs; Female; Gait; Hydrocortisone; Male; Pain; Reproducibility o | 2010 |
A case of acute kidney injury with marked hyperuricemia during mizoribine administration.
Topics: Acute Kidney Injury; Arthritis; Arthritis, Rheumatoid; Cranial Nerve Diseases; Female; Humans; Hyper | 2012 |
Crystal-induced inflammation; syndromes of gout and pseudogout.
Topics: Chondrocalcinosis; Gout; Humans; Inflammation; Syndrome; Synovitis; Uric Acid | 1963 |
Reactive nitrogen species scavenging, rather than nitric oxide inhibition, protects from articular cartilage damage in rat zymosan-induced arthritis.
Topics: Animals; Arthritis, Experimental; Cartilage, Articular; Disease Models, Animal; Dose-Response Relati | 2004 |
Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis.
Topics: Animals; Complement C6; Complement Membrane Attack Complex; Crystallization; Gout; Interleukin-8; Kn | 2004 |
The effects of epidural deracoxib on the ground reaction forces in an acute stifle synovitis model.
Topics: Analgesics; Analysis of Variance; Animals; Cross-Over Studies; Dog Diseases; Dogs; Dose-Response Rel | 2006 |
Kinetic gait and subjective analysis of the effects of a tachykinin receptor antagonist in dogs with sodium urate-induced synovitis.
Topics: Administration, Oral; Animals; Cross-Over Studies; Dog Diseases; Dogs; Female; Gait; Lameness, Anima | 2007 |
Chondrocalcinosis and chondrocalsynovitis. (pseudogout syndrome). Analysis of twenty-four cases.
Topics: Aged; Arthritis; Calcinosis; Calcium Phosphates; Cartilage, Articular; Female; Humans; Male; Middle | 1967 |
The role of the human synovial fibroblast in monosodium urate crystal-induced synovitis.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; 6-Ketoprostaglandin F1 alpha; Arachidonic Acids; Cells, | 1983 |
Increased inflammatory reactivity in newly formed lining tissue.
Topics: Air; Animals; Calcium Pyrophosphate; Carrageenan; Disease Models, Animal; Male; Rats; Rats, Inbred S | 1983 |
Passive range of motion, not isometric exercise, amplifies acute urate synovitis.
Topics: Acute Disease; Animals; Exercise Therapy; Isometric Contraction; Physical Exertion; Rabbits; Synovit | 1983 |
Lidocaine inhibits leukocyte migration and phagocytosis in monosodium urate crystal-induced synovitis in dogs.
Topics: Animals; Anti-Inflammatory Agents; Cell Migration Inhibition; Crystallization; Dogs; Knee Joint; Leu | 1983 |
[Arthroscopy in the diagnosis and treatment of microcrystalline synovitis].
Topics: Adult; Arthroscopy; Calcium Pyrophosphate; Crystallization; Female; Humans; Knee Joint; Male; Middle | 1982 |
[Uric acid-induced diseases. 1. Clinical picture, forms of manifestation].
Topics: Animals; Arteriosclerosis; Gout; Humans; Kidney Calculi; Kidney Diseases; Pruritus; Rats; Risk; Syno | 1980 |
Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis.
Topics: Calcium Pyrophosphate; Cells, Cultured; Chemokine CCL3; Chemokine CCL4; Chemokine CXCL1; Chemokines, | 1995 |
The application of atomic force microscopy for the detection of microcrystals in synovial fluid from patients with recurrent synovitis.
Topics: Arthritis; Calcium Phosphates; Calcium Pyrophosphate; Crystallization; Durapatite; Humans; Microscop | 1995 |
Gout: questions that still need to be answered.
Topics: Animals; Crystallization; Disease Models, Animal; Gout; Humans; Mice; Mice, Mutant Strains; Synoviti | 1995 |
Components generated locally as well as serum alter the phlogistic effect of monosodium urate crystals in vivo.
Topics: Animals; Blood Proteins; Chemotactic Factors; Crystallization; Injections, Subcutaneous; Leukocyte C | 1993 |
Acute gouty synovitis associated with "urate milk".
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Gouty; Bursitis; Crystallization; E | 1997 |
[A 40-year-old man with left knee pain and tumefaction].
Topics: Acute Disease; Adult; Arthritis, Gouty; Humans; Knee Joint; Male; Pain; Synovitis; Uric Acid | 2001 |
Effect of experimental synovitis on disposition of penicillin and oxytetracycline in neonatal calves.
Topics: Animals; Animals, Newborn; Cattle; Cattle Diseases; Male; Metabolic Clearance Rate; Oxytetracycline; | 1989 |
Questionable role of leukotriene B4 in monosodium urate (MSU)-induced synovitis in the dog.
Topics: Animals; Dinoprostone; Dogs; Female; Leukotriene B4; Male; Prostaglandins E; SRS-A; Synovial Fluid; | 1986 |
Clinical and laboratory studies of a distinctive type of arthritis observed in New Guinea.
Topics: Adolescent; Adult; Ankle Joint; Arthritis; Blood Protein Electrophoresis; Blood Sedimentation; Femal | 1969 |
Crystal synovitis.
Topics: Calcium Phosphates; Crystallization; Diphosphates; Humans; Synovial Fluid; Synovitis; Uric Acid | 1966 |
Crystal-induced inflammation in canine joints. I. An experimental model with quantification of the host response.
Topics: Animals; Arthritis; Calcium Phosphates; Diphosphates; Dogs; Injections, Intra-Articular; Synovitis; | 1966 |
[Differential diagnosis and therapy of gout and pseudo-gout].
Topics: Aged; Chondrocalcinosis; Crystallization; Diagnosis, Differential; Diphosphates; Female; Gout; Human | 1971 |
Intravascular degranulation of neutrophils: an important factor in inflammation?
Topics: Animals; Arthritis; Cytoplasmic Granules; Dogs; Humans; Inclusion Bodies; Inflammation; Microscopy, | 1972 |
Gout and pseudogout.
Topics: Adult; Aged; Arthritis; Calcium; Chondrocalcinosis; Crystallization; Diabetes Complications; Diet Th | 1973 |
Anti-inflammatory properties of 4,5-diphenyl-2-oxazolepropionic acid (oxaprozin).
Topics: Airway Obstruction; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; B | 1974 |
Urate crystal induced inflammation in dog joints: sequence of synovial changes.
Topics: Acid Phosphatase; Acute Disease; Animals; Chronic Disease; Crystallization; Dogs; Glucuronidase; Gou | 1974 |
Some metabolic aspects of diseases of the locomotor system.
Topics: Body Weight; Calcinosis; Calcium Phosphates; Cartilage; Chondrocalcinosis; Female; Gout; Humans; Mal | 1973 |
The chronicity of inflammation and its significance in rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Animals; Antibodies; Antigens; Arthritis, Rheumatoid; Autoimmune Diseases; C | 1968 |
Pharmacological investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 5. Activity on acute experimental synovitis in dogs.
Topics: Animals; Anti-Inflammatory Agents; Dogs; Female; Injections, Intra-Articular; Male; Phenylbutazone; | 1972 |
Crystal deposition in hyperparathyroidism.
Topics: Achilles Tendon; Apatites; Autopsy; Calcinosis; Calcium Phosphates; Crystallization; Fingers; Foot; | 1971 |
[Possibilities of the differential diagnosis of effusions from joints].
Topics: Acid Phosphatase; Arthritis, Rheumatoid; C-Reactive Protein; Diagnosis, Differential; Gout; Histiocy | 1971 |
Anti-inflammatory effect of the trypsin-kallikrein inhibitor in acute arthritis induced by urate crystals in rabbits.
Topics: Animals; Anti-Inflammatory Agents; Aprotinin; Arthritis; Complement System Proteins; Crystallography | 1970 |
[Proliferative synovitis after intra-articular injections of micro-crystals of sodium urate in rabbits. Preliminary note].
Topics: Animals; Arthritis, Rheumatoid; Freund's Adjuvant; Gout; Injections, Intra-Articular; Male; Rabbits; | 1969 |
Aseptic necrosis of the femoral head: associated diseases and evaluation of treatment.
Topics: Adult; Age Factors; Anemia, Sickle Cell; Bone Diseases; Female; Femoral Fractures; Femur Head; Fluor | 1970 |
Appearance of chemotactic activity following intra-articular injection of monosodium urate crystals: effect of colchicine.
Topics: Animals; Chemotaxis; Colchicine; Dogs; Injections, Intra-Articular; Sodium; Synovial Fluid; Synoviti | 1970 |
[Synovial fluid in arthritis urica. Sodium urate crystals as a key to the diagnosis and pathogenesis].
Topics: Diagnosis, Differential; Female; Gout; Humans; Inflammation; Male; Synovial Fluid; Synovitis; Uric A | 1971 |
[Crystal synovitis].
Topics: Animals; Calcinosis; Dogs; Humans; Microscopy, Polarization; Models, Biological; Synovial Fluid; Syn | 1968 |
Inhibition of rat adjuvant arthritis by a new immunosuppressive agent rubidomycin.
Topics: Animals; Antibiotics, Antineoplastic; Arthritis; Bone Resorption; Cellulitis; Freund's Adjuvant; Imm | 1968 |
[Gout and pseudogout].
Topics: Bradykinin; Calcinosis; Calcium; Female; Gout; Humans; Joint Diseases; Lysosomes; Male; Methods; Pep | 1968 |
Effect of anti-inflammatory agents on acute experimental synovitis in dogs.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Chlorpromazine; Codeine; Dogs; Gout; Hydrocortisone; Ind | 1966 |
[Synovitis due to crystals].
Topics: Humans; Synovitis; Uric Acid | 1966 |